Literature DB >> 232028

Long-term effect of sotalol on plasma lipids.

A Lehtonen, J Viikari.   

Abstract

1. We studied the effect on plasma lipids of sotalol given orally over a 12 month period to patients with essentially hypertension. 2. Plasma free fatty acid concentration was lower than initially at 1, 3, 6 and 12 months. The difference was significant (P less than 0.01) at 1 and 3 months. 3. Plasma cholesterol (VLDL + LDL-cholesterol) increased during treatment. Plasma total cholesterol increased from 5.49 +/- SD 0.94 mmol/l at the beginning to 6.37 +/- 1.10 mmol/l at 12 months (P less than 0.01). 4. HDL-cholesterol concentration and the ratio of HDL-cholesterol to total cholesterol decreased significantly. The ratios were 0.28 and 0.18 at the beginning and at 12 months respectively (P less than 0.001). 5. Plasma triglycerides increased simultaneously from 1.14 +/- 0.31 to 1.89 +/- 0.99 mmol/l (P less than 0.01).

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 232028     DOI: 10.1042/cs057405s

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  10 in total

Review 1.  Effects of acebutolol on the serum lipid profile.

Authors:  A Clucas; N Miller
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  HDL cholesterol and beta-adrenoceptor blocking agents in a 5 year multifactorial primary prevention trial.

Authors:  T A Miettinen; H Vanhanen; J K Huttunen; V Naukkarinen; S Mattila; T Strandberg; T Kumlin
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

Review 3.  The effects of antihypertensive drugs on serum lipids and lipoproteins. II. Non-diuretic drugs.

Authors:  R P Ames
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

Review 4.  The effects of diuretics and adrenergic-blocking agents on plasma lipids.

Authors:  J J Rohlfing; J D Brunzell
Journal:  West J Med       Date:  1986-08

Review 5.  Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  B N Singh; P Deedwania; K Nademanee; A Ward; E M Sorkin
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 6.  Pindolol--a beta-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations.

Authors:  W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

7.  Beta-blocker induced changes in the cholesterol: high-density lipoprotein cholesterol ratio and risk of coronary heart disease.

Authors:  B G Woodcock; N Rietbrock
Journal:  Klin Wochenschr       Date:  1984-09-17

Review 8.  Sotalol. An updated review of its pharmacological properties and therapeutic use in cardiac arrhythmias.

Authors:  A Fitton; E M Sorkin
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

9.  Effects of pindolol and metoprolol on plasma lipids and lipoproteins.

Authors:  C Pasotti; A Capra; G Fiorella; C Vibelli; S M Chierichetti
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

10.  Comparison of the metabolic effects of long-term treatment with pindolol or atenolol by hypertensive patients.

Authors:  A Lehtonen
Journal:  Cardiovasc Drugs Ther       Date:  1988-01       Impact factor: 3.727

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.